Company profile
Keros Therapeutics, Inc.
NASDAQ: KROS · Healthcare · Biotechnology
#274 of 1,422 Healthcare companies by revenuetop-decile growth
EA Score
71BFH 87DQ 62GM 52SS 54
v0.1 · 65/100 weight · provisional
↑ revenue growth (YoY), net margin · ↓ growth stability, listing tenure
Methodology →Revenue TTM
$33.2M
Rev growth YoY (TTM)
-84.5%
Net income (FY)
$87.0M
Employees
87
as of 2026-08-12
Market cap
$340.5M
as of 2026-08-12
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$244.1M$244.1M2025
Net income$87.0M$87.0M2025
Operating income$67.6M$67.6M2025
Total assets$338.0M$338.0M2025
Liabilities$34.9M$34.9M2025
Equity$303.1M$303.1M2025
Revenue trend
FY2020 – FY2025 · USD
FY20
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
License84%
Service, Other16%
By geography
Not disclosed.
The read
What is Keros Therapeutics, Inc.’s revenue?
Keros Therapeutics, Inc. booked $244.1M in FY2025 revenue, growing 6775% year over year — faster than 99% of Healthcare companies we track, at a 35.7% net margin.
Peers · Healthcare
LeMaitre Vascular, Inc.80B+American Well Corporation60CMesa Laboratories, Inc.78B+Definitive Healthcare Corp.53DSTAAR Surgical Company67BVaxart, Inc.72BNeighbors
Middlesex →Key facts
CEOJasbir S. Seehra
SectorHealthcare
IndustryBiotechnology
HeadquartersLexington, MA
ExchangeNASDAQ: KROS
Employees87
IPO date2020-04-08
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.